These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 19965918

  • 1. Effect of everolimus on cell viability in nonfunctioning pituitary adenomas.
    Zatelli MC, Minoia M, Filieri C, Tagliati F, Buratto M, Ambrosio MR, Lapparelli M, Scanarini M, Degli Uberti EC.
    J Clin Endocrinol Metab; 2010 Feb; 95(2):968-76. PubMed ID: 19965918
    [Abstract] [Full Text] [Related]

  • 2. Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.
    Zatelli MC, Minoia M, Martini C, Tagliati F, Ambrosio MR, Schiavon M, Buratto M, Calabrese F, Gentilin E, Cavallesco G, Berdondini L, Rea F, degli Uberti EC.
    Endocr Relat Cancer; 2010 Sep; 17(3):719-29. PubMed ID: 20554786
    [Abstract] [Full Text] [Related]

  • 3. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.
    Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC.
    Endocr Relat Cancer; 2007 Mar; 14(1):91-102. PubMed ID: 17395978
    [Abstract] [Full Text] [Related]

  • 4. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors.
    Hofland LJ, De Herder WW, Visser-Wisselaar HA, Van Uffelen C, Waaijers M, Zuyderwijk J, Uitterlinden P, Kros MJ, Van Koetsveld PM, Lamberts SW.
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3011-8. PubMed ID: 9284735
    [Abstract] [Full Text] [Related]

  • 5. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I.
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [Abstract] [Full Text] [Related]

  • 6. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
    Grozinsky-Glasberg S, Rubinfeld H, Nordenberg Y, Gorshtein A, Praiss M, Kendler E, Feinmesser R, Grossman AB, Shimon I.
    Mol Cell Endocrinol; 2010 Feb 05; 315(1-2):87-94. PubMed ID: 19815051
    [Abstract] [Full Text] [Related]

  • 7. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion.
    Murray RD, Kim K, Ren SG, Lewis I, Weckbecker G, Bruns C, Melmed S.
    J Clin Endocrinol Metab; 2004 Jun 05; 89(6):3027-32. PubMed ID: 15181094
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study.
    Florio T, Barbieri F, Spaziante R, Zona G, Hofland LJ, van Koetsveld PM, Feelders RA, Stalla GK, Theodoropoulou M, Culler MD, Dong J, Taylor JE, Moreau JP, Saveanu A, Gunz G, Dufour H, Jaquet P.
    Endocr Relat Cancer; 2008 Jun 05; 15(2):583-96. PubMed ID: 18509006
    [Abstract] [Full Text] [Related]

  • 9. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
    Saveanu A, Jaquet P, Brue T, Barlier A.
    Mol Cell Endocrinol; 2008 May 14; 286(1-2):206-13. PubMed ID: 18241980
    [Abstract] [Full Text] [Related]

  • 10. Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro.
    Zatelli MC, Piccin D, Bottoni A, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Taylor JE, Culler MD, Cavazzini L, degli Uberti EC.
    J Clin Endocrinol Metab; 2004 Oct 14; 89(10):5181-8. PubMed ID: 15472224
    [Abstract] [Full Text] [Related]

  • 11. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
    Saveanu A, Gunz G, Guillen S, Dufour H, Culler MD, Jaquet P.
    Neuroendocrinology; 2006 Oct 14; 83(3-4):258-63. PubMed ID: 17047391
    [Abstract] [Full Text] [Related]

  • 12. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.
    Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SW.
    Eur J Endocrinol; 2005 Apr 14; 152(4):645-54. PubMed ID: 15817922
    [Abstract] [Full Text] [Related]

  • 13. Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas.
    Padova H, Rubinfeld H, Hadani M, Cohen ZR, Nass D, Taylor JE, Culler MD, Shimon I.
    Mol Cell Endocrinol; 2008 May 14; 286(1-2):214-8. PubMed ID: 18276067
    [Abstract] [Full Text] [Related]

  • 14. Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.
    Gagliano T, Filieri C, Minoia M, Buratto M, Tagliati F, Ambrosio MR, Lapparelli M, Zoli M, Frank G, degli Uberti E, Zatelli MC.
    Pituitary; 2013 Mar 14; 16(1):91-100. PubMed ID: 22350942
    [Abstract] [Full Text] [Related]

  • 15. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
    Ibáñez-Costa A, Rivero-Cortés E, Vázquez-Borrego MC, Gahete MD, Jiménez-Reina L, Venegas-Moreno E, de la Riva A, Arráez MÁ, González-Molero I, Schmid HA, Maraver-Selfa S, Gavilán-Villarejo I, García-Arnés JA, Japón MA, Soto-Moreno A, Gálvez MA, Luque RM, Castaño JP.
    J Endocrinol; 2016 Nov 14; 231(2):135-145. PubMed ID: 27587848
    [Abstract] [Full Text] [Related]

  • 16. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
    Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A.
    J Clin Endocrinol Metab; 2001 Jul 14; 86(7):2976-81. PubMed ID: 11443154
    [Abstract] [Full Text] [Related]

  • 17. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U, Reichel M, Fett U, Saeger W, Quabbe HJ.
    J Clin Endocrinol Metab; 1994 Nov 14; 79(5):1416-23. PubMed ID: 7962337
    [Abstract] [Full Text] [Related]

  • 18. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro.
    Tulipano G, Bonfanti C, Milani G, Billeci B, Bollati A, Cozzi R, Maira G, Murphy WA, Poiesi C, Turazzi S, Giustina A.
    Neuroendocrinology; 2001 May 14; 73(5):344-51. PubMed ID: 11399907
    [Abstract] [Full Text] [Related]

  • 19. The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro.
    Gruszka A, Kunert-Radek J, Radek A, Pisarek H, Taylor J, Dong JZ, Culler MD, Pawlikowski M.
    Life Sci; 2006 Jan 11; 78(7):689-93. PubMed ID: 16115652
    [Abstract] [Full Text] [Related]

  • 20. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
    Fusco A, Gunz G, Jaquet P, Dufour H, Germanetti AL, Culler MD, Barlier A, Saveanu A.
    Eur J Endocrinol; 2008 May 11; 158(5):595-603. PubMed ID: 18426817
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.